Abstract

Background. The use of sodium polystyrene sulfonate in decreasing serum potassium has recently been questioned due to the lack of documented effectiveness. Methods. A retrospective cohort analysis of all hospitalized patients who received sodium polystyrene sulfonate over four months was performed. The change in serum potassium was noted over a period of 24 hours. Patients who received any other form of potassium-altering drug or treatment were excluded. Results. The administration of sodium polystyrene sulfonate reduced serum potassium by 16.7% (P < 0.001) as compared to the baseline serum potassium over a period of 24 hours. During this same time, no change in serum creatinine was identified (P = 0.73). In addition, there was no correlation between potassium and creatinine change (r2 = 0.0004 and P = 0.99). Patients with higher initial serum potassium (≥5.6 mEq/L) reduced their potassium concentration 4% more than those with initial serum potassium of <5.6 mEq/L; however, this reduction did not reach statistical significance (P = 0.32). There was no significant difference in the effectiveness of 15 gm and 30 gm resin preparation (P = 0.54). Thirteen deaths were noted in our cohort, of which one death was due to ischemic colitis. Conclusion. We conclude that sodium polystyrene sulfonate is effective in lowering serum potassium.

Highlights

  • Sodium polystyrene sulfonate (SPS) is a cation exchange resin used for the treatment of hyperkalemia

  • Potassium continued to decline over 24 hours and reached its minimum during 18 to 24 hours interval; there was no significant change in potassium between 12.5–18 hours and >18 hours intervals (P = 0.147)

  • No change was noted in the proportion of change in creatinine concentration during the same time period (P = 0.73) (Figure 3(b))

Read more

Summary

Introduction

Sodium polystyrene sulfonate (SPS) is a cation exchange resin used for the treatment of hyperkalemia. Despite its widespread use as a treatment modality for hyperkalemia, there is a paucity of data on SPS effectiveness in lowering serum potassium in human subjects. Due to these considerations, a recent review stated SPS use to be “largely unproven and potentially harmful” [20]. The administration of sodium polystyrene sulfonate reduced serum potassium by 16.7% (P < 0.001) as compared to the baseline serum potassium over a period of 24 hours. During this same time, no change in serum creatinine was identified (P = 0.73). We conclude that sodium polystyrene sulfonate is effective in lowering serum potassium

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.